

10/581,613 ~~myto~~

SPECIFICATION AMENDMENTS

At page 1, line 1, please insert the following:

The instant application is a 371 of PCT CA04/02084, filed December 6, 2005, now abandoned, which claims the benefit of US Provisional Patent Application 60/526,971, filed December 5, 2004, now abandoned, and US Provisional Patent Application 60/568,225, filed May 6, 2004, now abandoned.

In the paragraph at page 6, line 5 to line 10, please insert the following:

Figure 6. Sequence data showing clones are unique and the id of the CDR regions that play a role in neutralization. ~~(see PDF files for improved resolution)~~ Figure 6A aligns G1-light (SEQ ID No. 16); G3-light (SEQ ID No. 10); G6-light (SEQ ID No. 17), G7-light (SEQ ID No. 11), G8-light (SEQ ID No. 18), G10-light (SEQ ID No. 13), G15-light (SEQ ID No. 44) and G18-light (SEQ ID No. 14). Figure 6B aligns G1-heavy (SEQ ID No. 7), G3-heavy (SEQ ID No. 1), G6-heavy (SEQ ID No. 8), G15-heavy (SEQ ID No. 45) and G18-heavy (SEQ ID No. 5). The data shows that none of the VH or VL genes of the anti-SARS neutralizing or Western immunoblot positive mAbs are the same. This means that each hybridoma was derived from a unique B cell and target SARS using different proteins. (i.e. not the same clone picked several times)

In the paragraph at page 6, line ¹¹5 to line ¹²10, please insert the following:

Figure 7. SARS-specific monoclonal antibodies, Heavy chains (VH) amino acid sequences: F26G3-VH (SEQ ID No. 1); F26G7-VH (SEQ ID No. 2); F26G9-VH (SEQ ID No. 3); F26G10-VH (SEQ ID No. 4); F26G18 (SEQ ID No. 5); F26G19-VH (SEQ ID No. 6); F26G1-VH (SEQ ID No. 7); F26G6-VH (SEQ ID No. 8); and F26G8-VH (SEQ ID No. 9).

~~myto~~ 8/18/09

10/581, 613 ~~MPD~~

In the paragraph at page 6, line ¹³5 to line ¹⁴10, please insert the following: ~~MPD~~ 8/18/09

Figure 8. SARS-specific monoclonal antibodies, Light chains (VL) amino acid sequences: F26G3-VL (SEQ ID No. 10); F26G7-VL (SEQ ID No. 11); F26G9-VL (SEQ ID No. 12); F26G10-VL (SEQ ID No. 13); F26G18-VL (SEQ ID No. 14); F26G19-VL (SEQ ID No. 15); F26G1-VL (SEQ ID No. 16); F26G6-VL (SEQ ID No. 17); and F26G8-VL (SEQ ID No. 18).

In the paragraph at page 6, line ¹⁵5 to line ¹⁶10, please insert the following: ~~MPD~~ 8/18/09

Figure 9. SARS-specific monoclonal antibodies, Heavy chains (VH) nucleotide sequences: F26G3-VH (SEQ ID No. 19); F26G7-VH (SEQ ID No. 20); F26G9-VH (SEQ ID No. 21); F26G10-VH (SEQ ID No. 22); F26G18-VH (SEQ ID No. 23); F26G19-VH (SEQ ID No. 24); F26G1-VH (SEQ ID No. 25); F26G6-VH (SEQ ID No. 26); and F26G8-VH (SEQ ID No. 27).

In the paragraph at page 6, line ¹⁷5 to line ¹⁸10, please insert the following: ~~MPD~~ 8/18/09

Figure 10. SARS-specific monoclonal antibodies, Light chains (VL) nucleotide sequences: F26G3-VL (SEQ ID No. 28); F26G7-VL (SEQ ID No. 29); F26G9-VL (SEQ ID No. 30); F26G10-VL (SEQ ID No. 31); F26G18-VL (SEQ ID No. 32); F26G19-VL (SEQ ID No. 33); F26G1-VL (SEQ ID No. 34); F26G6-VL (SEQ ID No. 35); and F26G8-VL (SEQ ID No. 36).

At Page 31, beneath Table 3, at line 21, please insert the following:

CorV1 Forward – SEQ ID No. 37; CorV 389 Reverse 1 – SEQ ID No. 38; CorV 154 Forward 2 – SEQ ID No. 39; CorV 310 Reverse2 – SEQ ID No. 40; Forward Primer – SEQ ID No. 41; Reverse Primer – SEQ ID No. 42; TaqMan MGB probe – SEQ ID No. 43.